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Objectives: Until recently, the European Committee on Antimicrobial Susceptibility Testing 25 
(EUCAST) recommended the cefoxitin disk to screen for mecA-mediated betalactam resistance in 26 
Staphylococcus pseudintermedius. A recent study indicated that cefoxitin was inferior to oxacillin 27 
in this respect. We have re-evaluated cefoxitin and oxacillin disks for screening for methicillin 28 
resistance in S. pseudintermedius. Methods: We included 224 animal and human S. 29 
pseudintermedius isolates from Europe (n=108) and North America (n=116), of which 109 were 30 
mecA-positive. Disk diffusion was performed per EUCAST recommendations using 30 µg cefoxitin 31 
and 1 µg oxacillin disks from three manufacturers and Mueller-Hinton agar from two 32 
manufacturers. Results: Cefoxitin inhibition zones ranged from 6-33 mm for mecA-positive S. 33 
pseudintermedius (MRSP) and from 29-41 mm for mecA-negative S. pseudintermedius (MSSP). The 34 
corresponding oxacillin zone intervals were 6-20 mm and 19 – 30 mm. For cefoxitin 16% (14.8%-35 
18.0%, 95% CI) of the isolates were in the area where positive and negative results overlapped. For 36 
oxacillin the corresponding number was 2% (1.6%-2.9%). For oxacillin a breakpoint of S, ≥20 mm 37 
and R,<20 mm resulted in only 0.4% and 1.1% VME and ME rates respectively.  38 
Conclusions: This investigation confirms that the 1 µg oxacillin disk predicts mecA-mediated 39 
methicillin resistance in S. pseudintermedius better than the 30 µg cefoxitin disk. For a 1 µg 40 
oxacillin disk we propose that 20 mm should be used as cut off for resistance i.e. isolates with a 41 
zone diameter <20 mm are resistant to all beta- lactam antibiotics except those with effect against 42 
methicillin resistant staphylococci. 43 
 44 
Introduction 45 
Staphylococcus pseudintermedius is a coagulase-positive Staphylococcus species adapted 46 
to Canidae and one of the most important bacterial pathogens in dogs but also causes 47 
infections in humans including serious infections (1-4). The introduction of matrix-assisted 48 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for bacterial 49 
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identification has shown that the incidence of S. pseudintermedius infections in humans is 50 
probably underestimated due to mis-identification as Staphylococcus aureus (4-6).  51 
Methicillin (β-lactam)-resistant S. pseudintermedius (MRSP) was first reported in 1999 in 52 
North America (7) and in 2006 in Europe (8). Since then, five MRSP lineages (CC45, 68, 71, 53 
112, 258) with specific traits regarding antimicrobial resistance, genetic diversity and 54 
geographical distribution have spread globally (1, 9). Hitherto, according to our 55 
knowledge, only mecA-based resistance have been reported in S. pseudintermedius. 56 
Variable MRSP prevalence among clinical isolates (1-33%) has been reported by recent 57 
studies from different geographical areas and study populations (2, 10-15). A study in the 58 
United States (US) showed that the prevalence of  methicillin resistance in canine clinical 59 
isolates increased from <5% in 2001 to nearly 30% in 2007 . Some MRSP clones such as 60 
sequence type (ST) 71 display resistance to virtually all antimicrobial agents licensed for 61 
veterinary use, posing one of the most challenging problems so far encountered in the 62 
antimicrobial management of veterinary infectious diseases. According to a recent review, 63 
approximately two thirds of MRSP isolates submitted to the multilocus sequence typing 64 
(MLST) database originate from skin samples associated with pyoderma, surgical site and 65 
wound infections (1).  66 
Cefoxitin is endorsed by both the European Committee on Antimicrobial Susceptibility 67 
Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) as the 68 
preferred agent for detecting methicillin-resistant Staphylococcus aureus (MRSA) and 69 
methicillin-resistant coagulase-negative Staphylococcus (MRCoNS) isolates by disk 70 
diffusion (16-18). In contrast, there has been divergence between EUCAST and CLSI on the 71 
antimicrobial agent to use for the detection of MRSP by disk diffusion. EUCAST has 72 
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advocated for the use of cefoxitin, whereas CLSI recommends oxacillin for detection of 73 
MRSP (17, 18). Previous studies have shown that cefoxitin growth inhibition zone 74 
diameter breakpoints recommended for detection of MRSA (susceptible, ≥22 mm; 75 
resistant, <22 mm) and MRCoNS (S, ≥25 mm; R, <25 mm) are not reliable for MRSP (19). In 76 
2012, based on a study of 1,146 S. pseudintermedius isolates originating from different 77 
regions in the US, Bemis et al. proposed an epidemiological cut-off value for non-wildtype 78 
of ≤30 mm to maximize sensitivity (97%) and specificity (92%) for predicting methicillin  79 
resistance by cefoxitin disk diffusion (20). Our group further investigated 243 S. 80 
pseudintermedius isolates to identify the most suitable cefoxitin breakpoint to distinguish 81 
between MSSP and MRSP. The isolates were predominantly of European origin and the 82 
results indicated a breakpoint of S, ≥35 mm and R, <35 mm with only two (0.4%) major 83 
errors (ME) and one (0.2%) very major error (VME) (unpublished own data). On the basis 84 
of these data, these breakpoints were added to the EUCAST breakpoint table 4.0 85 
published January 2014 (21).However, in a subsequent study Wu et al. showed that the 86 
EUCAST breakpoint produced a significant number of major errors (ME) in a study using 87 
115 human and veterinary “Staphylococcus intermedius group” isolates (111 S. 88 
pseudintermedius and four Staphylococcus delphini isolates) from the US. The authors 89 
concluded that cefoxitin disk diffusion is not reliable for MRSP detection and that 90 
laboratories should perform oxacillin disk diffusion or broth-based minimum inhibitory 91 
concentration tests (22). This was confirmed by Yarbrough et al. who found that none of 92 
12 MRSP isolates were detected by cefoxitin disk diffusion whereas all 12 were detected 93 
using oxacillin disk diffusion (4). 94 
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The current study was conducted to re-evaluate disk diffusion breakpoints using cefoxitin 95 
(30 µg disk) and oxacillin (1 µg disk) disk diffusion to detect mecA-mediated β-lactam 96 
resistance in S. pseudintermedius using disks from three manufacturers and Mueller-97 
Hinton agar (MHA) from two manufacturers. For the present evaluation, our strain 98 
collection included strains from both Europe and North America to take the marked 99 
differences in the distribution of clonal lineages existing between these two geographical 100 
regions into account (1).  101 
 102 
Materials and Methods 103 
Bacterial isolates 104 
A total of 224 clinical S. pseudintermedius isolates were tested, including 115 mecA-105 
negative (MSSP) isolates and 109 mecA-positive (MRSP) isolates. The isolates were 106 
obtained from colleagues in Europe and North America representing a convenience 107 
sampling and included the 111 S. pseudintermedius isolates described by Wu and 108 
colleagues. Sixty-seven isolates from dogs and six from cats isolated between 2006 and 109 
2011 were from a strain collection at the National Veterinary Institute in Sweden (SVA). 110 
Forty-nine of these isolates were from different European countries, three from Canada 111 
and two from the US (23). Forty canine isolates isolated between 2008 and 2011 were 112 
from the Norwegian Veterinary Institute (NVI). The remaining 111 isolates described by 113 
Wu et al. were obtained and included in this present study (the four S. delphini isolates 114 
were not included) (22) to investigate if the difference between the data published by Wu 115 
et al. and those obtained in our previous investigation were explained by differences 116 
between isolates from Europe and isolates from North America. The isolates originated 117 
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from humans (n=45) and animals (n=66), including dogs, cats, birds and pigs. MLST data 118 
were available for 76 of the 78 MRSP isolates from the SVA and NVI collections using the 119 
MLST_5 scheme for 52 isolates (SVA) and the MLST_7 scheme for 24 isolates (NVI) (24, 120 
25). A total of 18 different MLST types including world epidemic lineages such as ST68, 121 
ST71 and ST258 were represented in the study. While no MLST data were available for the 122 
isolates described by Wu and co-workers, repetitive-sequence PCR (rep-PCR) 123 
demonstrated the collection was composed of six different rep-PCR clonal lineages 124 
(designated A to F) (22). No correlation between rep-PCR clonal type and antimicrobial 125 
susceptibility data was encountered, implying results were not due to a specific S. 126 
pseudintermedius lineage. All isolates were identified in the laboratory at Växjö to the 127 
species level with MALDI-TOF MS using the Microflex system with the MALDI Biotyper 3.1 128 
software and MBT 6903 Library (Bruker Daltonics, Bremen, Germany) per the 129 
manufacturer’s instructions. mec status was determined by the contributing laboratories: 130 
SVA (mecA) (26) and NVI (mecA) (27), or as described in Wu et al. (mecA and mecC) (22). 131 
In case of discrepancy between the mec status and the phenotypic results obtained in this 132 
study, the mec status were confirmed by a real-time PCR assay that tested for both mecA 133 
and mecC (28). The study did not require patient consent or ethical approval since isolates 134 
were not associated with any identifiable patient information. 135 
 136 
Antimicrobial susceptibility testing 137 
Disk diffusion was performed according to EUCAST recommendations (29) using 30 µg 138 
cefoxitin and 1 µg oxacillin disks from Oxoid/ThermoFisher Scientific (Basingstoke, UK), 139 
Mast Diagnostics (Bootle, UK) and Becton Dickinson (Heidelberg, Germany). All isolates 140 
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were tested in parallel from the same inoculum on in-house prepared MHA plates using 141 
pre-formulated powder from ThermoFisher Scientific (Oxoid agar) and Becton Dickinson 142 
(BBL agar), and commercial plates from Becton Dickinson (BBL agar). Staphylococcus 143 
aureus ATCC® 29213 was used as quality control.   144 
 145 
Data analysis 146 
The ability of cefoxitin (30 µg) and oxacillin (1 µg) disks to predict the presence of mecA-147 
mediated β-lactam resistance in S. pseudintermedius was evaluated by 1) comparing the 148 
degree of measurements placed in the interval where both mecA-negative and mecA-149 
positive isolates presented values  (disregarding the measurements of the aberrant strain, 150 
and 2) the number of major Errors (ME) and very major errors (VME) for the present 151 
EUCAST breakpoint for cefoxitin (S, ≥35 mm and R, <35 mm) and for oxacillin using the 152 
CLSI breakpoint (S, ≥18 mm and  R, ≤17 mm) as well as an alternative breakpoint (S, ≥20 153 
mm and  R, <20 mm) based on the present study (total isolate set). ME and VME were 154 
calculated based on the number of susceptible and the number of resistant tests, 155 
respectively.  156 
Analyses on performance were done disregarding the clearly aberrant mecA-negative 157 
isolate (see results) for a) the total aggregated set of measurements:2,007 data points 158 
(223 isolates × 3 different disk manufacturers × 3 different MHAs), b) for isolates from 159 
Europe vs isolates from North America and c) for each of the individual combinations of 160 
MHAs and disk brands. Comparison of the distributions of zone diameters were 161 
performed using the Mann-Whitney U test, p>0.05 were used as significance level 162 
 163 
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Results 164 
The results for the cefoxitin 30 µg and oxacillin 1 µg disk screening tests are shown in 165 
Table 1/Figure 1 and Table 2/Figure 2, respectively. One mecA- (and mecC) negative 166 
isolate was clearly aberrant by oxacillin testing with an inhibition zone size between 14-16 167 
mm for oxacillin and 28-29 mm for cefoxitin. This isolate was also clearly resistant in the 168 
investigation by Wu et al. (22), the mechanism of resistance for this has not been 169 
elucidated. Disregarding this isolate, the inhibition zone sizes of isolates from Europe and 170 
North America spanned over similar ranges; i.e., a maximum difference of 2 mm for both 171 
cefoxitin and oxacillin except for mecA-positive isolates tested against cefoxitin where 172 
isolates from Europe ranged from 6-33 mm versus 21-32 mm for isolates from North 173 
America (Tables 1 and 2). Nevertheless, comparison of isolates from Europe and North 174 
America for each of the four distributions; cefoxitin mecA-negative, cefoxitin  mecA-175 
positive, oxacillin mecA-negative and oxacillin mecA-positive were significantly different 176 
(p<0.0001, p<0.01, p<0.002 and, p<0.0001 ). Measurements from the individual disk and 177 
MHA combinations only showed minor differences (i.e., maximum difference in minimum 178 
or maximum values of 1-2 mm [Tables 1 and 2]).  179 
For the aggregated dataset for the 30 µg cefoxitin disks, 16% (14.8%-18.0%, 95% CI) of the 180 
zone size measurements were in the region (29 -33 mm) where both mecA-negative and 181 
mecA-positive isolates tested (Table 1).  For the 1 µg oxacillin disks, only 2% (1.6%-2.9%, 182 
95% CI) of the measurements were in the region (19-20 mm) where both mecA-negative 183 
and mecA-positive isolates tested (Table 2). Furthermore, the vast majority of the mecA-184 
positive isolates displayed no zone of inhibition with the 1 µg oxacillin disk which provides 185 
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much better separation between the mecA-negative and the mecA-positive populations 186 
compared to the 30 µg cefoxitin disk (Figure 1 and Figure 2).  187 
For the 1 ug oxacillin disk the number of MEs and VMEs using both the CLSI breakpoint (S, 188 
≥18 mm and R, ≤17 mm) and the breakpoint suggested on the data in this publication (S, 189 
≥20 mm and R,<20 mm) are shown in Table 1 and 2 both for the total dataset as well as 190 
for the individual datasets (excluding the aberrant mecA-negative isolate). The CLSI 191 
breakpoint resulted in a total of nine mecA-positive isolates (six European and three North 192 
American isolates, 40 data points) being reported as susceptible resulting in a VME rate of 193 
4.1%, and one mecA-negative isolate (one North American isolate, 9 data points) would be 194 
reported as resistant; i.e., 0.9% ME. In contrast, changing the breakpoint to S, ≥20 mm and  195 
R,<20 mm the corresponding VME and ME rates were 0.4% (one European isolate, 4 data 196 
points) and 1.1% (2 North American isolates, 11 data points), respectively.  197 
  198 
Discussion 199 
Detection of mecA-based methicillin resistance using cefoxitin or oxacillin disks is in fact a 200 
dichotomous screening test where the ideal substance has a cutoff that clearly 201 
distinguishes between mecA-positive and mecA-negative isolates with no or very little 202 
overlap. In this study, where S. pseudintermedius isolates from Europe and North America 203 
were tested by using disks from three different manufacturers and MHA from two 204 
different manufacturers, oxacillin was markedly better than cefoxitin in separating mecA-205 
negative from-positive isolates. By the 1 µg oxacillin disk, only 2% of the total number of 206 
data points were in the interval where zone sizes for mecA-negative and mecA-positive 207 
isolates overlapped (it was not possible to classify an isolate as either susceptible or 208 
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resistant) in comparison to 16% of the data points for the 30 µg cefoxitin disk diffusion. 209 
Thus, our previous finding that cefoxitin disk diffusion can reliably differentiate between 210 
mecA-negative and mecA-positive isolates of S. pseudintermedius has been modified 211 
based upon our current data where a greater variety of strains, disks and media were 212 
assayed. Furthermore, the oxacillin disk had the advantage that the majority of mecA-213 
positive isolates did not exhibit any zone of growth inhibition (they grew up to the edge of 214 
the disk), permitting good separation of MSSP and MRSP.  215 
Our data confirm the recommendation made by Wu et al. in favour of using oxacillin disk 216 
diffusion for detection of methicillin resistance in S. pseudintermedius (22). However, 217 
using the breakpoint suggested by Wu et al (the breakpoint adopted by CLSI) nine (8%) of 218 
the mecA-positive isolates, would be classified as false susceptible in comparison to one 219 
isolate (0.9%) using a breakpoint of S, ≥20 mm and R, <20 mm. In a previous study, Bemis 220 
et al. also found two PBP2a-positive isolates that displayed zone sizes greater than 17 mm 221 
(18 mm and 23 mm) (19), (Bemis personal communication). 222 
Interestingly six of the nine isolates were of European origin and none of the three North 223 
American isolates were false susceptible in all tested variants, providing a possible 224 
explanation for the difference found in this evaluation compared to the evaluation by Wu 225 
et al (22). Accordingly, for both cefoxitin and oxacillin the zone size distribution of isolates 226 
from Europe were significantly different from the North American isolates possibly 227 
reflecting differences in clonal distribution between Europe and North America.  228 
The findings in this study stresses the need for testing isolates from different clonotypes 229 
and to use disks and media from more manufacturers when setting breakpoints. Thus, for 230 
the 1 µg oxacillin disks, we propose that 20 mm is a more appropriate breakpoint to 231 
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distinguish between mecA-negative (zone diameter ≥20 mm) and mecA-positive (zone 232 
diameter <20 mm) isolates. This new breakpoint should reduce the frequency of VME 233 
(resistant isolates that test as susceptible) compared to the current CLSI breakpoint.  The 234 
breakpoints generated by this study are now accepted by the EUCAST (EUCAST breakpoint 235 
table v 7.1, 2017 (30). 236 
The inclusion of media and disks from different manufacturers which is an integrated part 237 
of EUCAST method development is a strength and demonstrates study originality since it 238 
incorporates the unavoidable variation in materials between manufacturers. An important 239 
limitation of the study is that the strain collection does not include isolates from Africa, 240 
Asia, or Australia which potentially could affect the proposed breakpoints. We did not test 241 
all isolates for mecC, however, isolates resistant for cefoxitin or oxacillin by disk diffusion, 242 
but negative for mecA were tested for mecC. Nevertheless, we cannot exclude that among 243 
the phenotypically susceptible isolates there were mecC-positive isolates, why our findings 244 
only apply for mecA-mediated β-lactam resistance (as reflected in the title).  245 
 246 
In conclusion, the present investigation confirms the findings from previous studies that 247 
oxacillin is better than cefoxitin for detection of mecA-mediated β-lactam resistance in S. 248 
pseudintermedius. As a result of this study, oxacillin is now recommended by CLSI and 249 
EUCAST for detecting mecA-mediated β-lactam resistance in S. pseudintermedius. This 250 
outcome contributes to optimize MRSP detection in both veterinary and human diagnostic 251 
laboratories and has therefore important implications for antimicrobial treatment in both 252 
populations. 253 
 254 
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Table 1.  Cefoxitin 30 µg disk inhibition zone sizes (mm), Major errors (ME) and Very Major errors (VME) using a breakpoint for S, ≥34 mm and R, <35 265 
mm for S. pseudintermedius isolates (n=223*) obtained from Europe and North America for the total number measurements and for individual 266 
subgroups. 267 
 268 
                                             269 
 270 
*271 
D272 
at273 
a 274 
fo275 
r 276 
the aberrant mecA/C-negative strain with cefoxitin readings of 28-29 mm and oxacillin readings of 14-16 mm are omitted. 277 
** Percentage of measurements that overlap between the zone sizes for mecA-negative and mecA-positive isolates. The interval is greater for all 278 
media/disks combined than for each individual media as the overlapping zones differ for the individual media/disks  279 
MHA 
Manufacturer 
Disk 
Manufacturer 
Number of 
measurrements 
Zone diameter, 
mm 
Interval (mm) with 
measurements from both 
mecA negative and mecA 
positive isolates  
(% of total values)  
 
Number (%) 
of ME 
(Breakpoint 
R<35 mm) 
Number (%) 
VME 
(Breakpoint 
S≥34 mm) 
 
mecA-
positive 
mecA-
negative* 
All 
  Europe  
  North America 
All 
All 
All 
2007 (223x3x3) 6-33 29-41   29-33 (16.3)** 376 (36.3%) 0 (0%) 
972 (108 x3x3) 6-33 31-40 31-33 (6.9%) 68 (18.4%) 0 (0%) 
1035 (115 x3x3) 14-32 29-41 29-32 (12.2%) 308 (46.2%) 0 (0%) 
BBL commercial 
BD 223 (223x1x1) 10-31 29-40 29-31 (8.0%) 64 (55.7%) 0 (0%) 
Mast 223 (223x1x1) 12-32 29-40 29-32 (9.8%) 59 (51.3%) 0 (0%) 
Oxoid 223 (223x1x1) 9-32 30-40 30-32 (6.7%) 45 (39.1%) 0 (0%) 
BBL prepared in-
house  
BD 223 (223x1x1) 9-32 31-40 31-32 (6.3%) 34 (29.6%) 0 (0%) 
Mast 223 (223x1x1) 10-32 31-41 31-32 (5.8%) 26 (22.6%) 0 (0%) 
Oxoid 223 (223x1x1) 6-33 31-41 31-33 (7.1%) 24 (20.9%) 0 (0%) 
Oxoid prepared 
in-house 
BD 223 (223x1x1) 6-32 30-40 31-32 (6.3%) 51 (44.3%) 0 (0%) 
Mast 223 (223x1x1) 6-33 30-40 30-33 (14.7%) 41 (35.7%) 0 (0%) 
Oxoid 223 (223x1x1) 6-33 31-41 31-33 (9.4%) 32 (27.8%) 0 (0%) 
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Table 2. Oxacillin 1 µg disk inhibition zone sizes (mm), Major errors (ME) and Very Major errors (VME) using breakpoint for S, ≥20 mm and R, <20 mm 281 
and S, ≥18 mm and R, ≤17 mm for S. pseudintermedius isolates (n=223*) obtained from Europe and North America for the total number measurements 282 
and for individual subgroups. 283 
MH Agar 
Manufacturer 
Disk 
Manufacturer 
Number of 
measurrements Zone diameter, 
mm 
Interval (mm) with 
measurements from both 
mecA negative and mecA 
positive isolates  
(Pct of total values)  
 
Number (%) of 
ME (Breakpoint 
R≤17 mm) 
Number (%) 
VME 
(Breakpoint 
S≥18 mm) 
Number (%) 
of ME 
(Breakpoint 
R<20mm) 
Number (%) 
VME 
(Breakpoint 
S≥20 mm) 
 mecA-
positive 
mecA-
negative* 
    
All 
  Europe  
  North America 
All 
All 
All 
2007 (223x3x3) 6-20 19-30 19-20 (2.2%)** 9 (0.9%) 40 (4.1%) 11 (1.1%) 4 (0.4%) 
972 (108 x3x3) 6-20 20-29 20 (0.9%) 0 (0.0%) 32 (4.9%) 0 (0.0%) 4 (0.6%) 
1035 (115 x3x3) 6-19 19-30 19 (0.2%) 9 (1.4%) 8 (2.4%) 11 (1.7%) 0 (0.0%) 
BBL commercial 
BD 223 (223x1x1) 6-19 19-28 19 (1.3%) 1 (0.9%) 4 (3.7%) 2 (1.8%) 0 (0.0%) 
Mast 223 (223x1x1) 6-18 19-28 - 1 (0.9%) 3 (2.8%) 2 (1.8%) 0 (0.0%) 
Oxoid 223 (223x1x1) 6-20 20-29 20 (1.3%) 1 (0.9%) 4 (3.7%) 1 (0.9%) 1 (0.9%) 
BBL prepared in-
house  
BD 223 (223x1x1) 6-19 20-28 - 1 (0.9%) 5 (4.6%) 1 (0.9%) 0 (0.0%) 
Mast 223 (223x1x1) 6-19 20-29 - 1 (0.9%) 5 (4.6%) 1 (0.9%) 0 (0.0%) 
Oxoid 223 (223x1x1) 6-19 20-28 - 1 (0.9%) 4 (3.7%) 1 (0.9%) 0 (0.0%) 
Oxoid prepared 
in-house 
BD 223 (223x1x1) 6-20 20-29 20 (0.9%) 1 (0.9%) 4 (3.7%) 1 (0.9%) 1 (0.9%) 
Mast 223 (223x1x1) 6-20 20-29 20 (1.8%) 1 (0.9%) 6 (5.5%) 1 (0.9%) 1 (0.9%) 
Oxoid 223 (223x1x1) 6-20 21-30 - 1 (0.9%) 5 (4.6%) 1 (0.9%) 1 (0.9%) 
*Data for the aberrant mecA/C-negative strain with cefoxitin readings of 28-29 mm and oxacillin readings of 14-16 mm are omitted  284 
** Percentage of measurements that overlap between the zone sizes for mecA-negative and mecA-positive isolates. The interval is greater for all 285 
media/disks combined than for each individual media as the overlapping zones differ for the individual media/disks   286 
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Figure 1. Cefoxitin 30 µg disk inhibition zone sizes versus mecA status for the 224 S. 287 
pseudintermedius isolates from Europe and North America (2,016 data points, each isolate 288 
tested using disk and media from three manufacturers [3 ×3 ×224 = 2,016]). 289 
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Figure 2. Oxacillin 1 µg disk inhibition zone sizes versus mecA status for 224 S. 292 
pseudintermedius isolates obtained from Europe and North America (2,016 data points, 293 
each isolate tested using disk and media from three manufacturers [3 ×3 ×224 = 2,016]). 294 
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